WT1 and myelodysplastic syndrome: Anguille et al. [34] explored the efficacy of a vaccine based on autologous DCs loaded with three different constructs of WT1 in patients in first CR at high risk of relapse after chemotherapy, as defined by prior MDS/MPN, the persistence of WT1 mRNA, or FLT3-ITD mutation.